COUNTERPOINT: Should Inhaled Antibiotic Therapy Be Used Routinely for the Treatment of Bacterial Lower Respiratory Tract Infections in the ICU Setting? No

Chest

Volumn 151, Issue 4, 2017, Pages 740-743

  Kollef, Marin H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CILASTATIN PLUS IMIPENEM; COLISTIN; GENTAMICIN; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; BACTERIAL LOWER RESPIRATORY TRACT INFECTION; DRUG CONCENTRATION; DRUG MEGADOSE; DRUG PENETRATION; EDITORIAL; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INTENSIVE CARE; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MUTATION PREVENTION CONCENTRATION; NEBULIZER; NONHUMAN; PARTICLE SIZE; TRACHEOBRONCHITIS; VENTILATOR ASSOCIATED PNEUMONIA; VENTILATOR ASSOCIATED TRACHEOBRONCHITIS; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; INTENSIVE CARE UNIT; RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS; RESPIRATORY TRACT INFECTIONS;

EID: 85017106605     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.11.007     Document Type: Editorial

References (20)

1. 1 Kollef, M.H., Sherman, G., Ward, S., Fraser, V.J., Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:2 (1999), 462–474.
2. 2 Bell, B.G., Schellevis, F., Stobberingh, E., Goossens, H., Pringle, M., A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis, 14, 2014, 13.
3. 3 Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. The Review on Antimicrobial Resistance. Chaired by Jim O'Neill. December 2014. https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf. Accessed April 13, 2016.
4. 4 Solé-Lleonart, C., Roberts, J.A., Chastre, J., et al. Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines. Clin Microbiol Infect 22:4 (2016), 359–364.
5. 5 Martin-Loeches, I., Povoa, P., Rodríguez, A., et al. Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study. Lancet Respir Med 3:11 (2015), 859–868.
6. 6 Prasad, P., Sun, J., Danner, R.L., Natanson, C., Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 54:12 (2012), 1699–1709.
7. 7 Ramirez, J., Dartois, N., Gandjini, H., Yan, J.L., Korth-Bradley, J., McGovern, P.C., Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 57:4 (2013), 1756–1762.
8. 8 Awad, S.S., Rodriguez, A.H., Chuang, Y.C., et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 59:1 (2014), 51–61.
9. 9 Rodvold, K.A., George, J.M., Yoo, L., Penetration of anti-infective agents into pulmonary epithelial lining fluid. Clin Pharmacokinet 50:10 (2011), 637–664.
10. 10 Olofsson, S.K., Cars, O., Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis 45:suppl 2 (2007), S129–S136.
11. 11 Kollef, M.H., Hamilton, C.W., Montgomery, A.B., Aerosolized antibiotics: do they add to the treatment of pneumonia?. Curr Opin Infect Dis 26:6 (2013), 538–544.
12. 12 Boe, J., Dennis, J.H., O'Driscoll, B.R., et al. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J 18:1 (2001), 228–242.
13. 13 Le, J., Ashley, E.D., Neuhauser, M.M., et al. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 30:6 (2010), 562–584.
14. 14 Russell, C.J., Shiroishi, M.S., Siantz, E., Wu, B.W., Patino, C.M., The use of inhaled antibiotic therapy in the treatment of ventilator-associated pneumonia and tracheobronchitis: a systematic review. BMC Pulm Med, 16(1), 2016, 40.
15. 15 Valachis, A., Samonis, G., Kofteridis, D.P., The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med 43:3 (2015), 527–533.
16. 16 Hsieh, T.C., Chen, F.L., Ou, T.Y., Jean, S.S., Lee, W.S., Role of aerosolized colistin methanesulfonate therapy for extensively-drug-resistant Acinetobacter baumannii complex pneumonia and airway colonization. J Microbiol Immunol Infect 49:4 (2014), 523–530.
17. 17 Liu, Y.Y., Wang, Y., Walsh, T.R., et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16:2 (2016), 161–168.
18. 18 van Duin, D., Doi, Y., Outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae: are we at the end of the road?. J Clin Microbiol 53:10 (2015), 3116–3117.
19. 19 Wunderink, R.G., Welkommen to our world. Emergence of antibiotic resistance with selective decontamination of the digestive tract. Am J Respir Crit Care Med 181:5 (2010), 426–427.
20. 20 McCoy, K.S., Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N Engl J Med 357:22 (2007), 2310–2311.